LA JOLLA PHARMACEUTICAL CO Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-05-06: Study NCT06487585; Company role Collaborator; Phase Phase 4; Status Recruiting.
- 2023-12-04: Study NCT06122987; Company role Collaborator; Phase Phase 4; Status Unknown.
- 2023-04-17: Study NCT05824767; Company role Collaborator; Phase Phase 4; Status Completed.
- 2022-06-28: Study NCT04901169; Company role Collaborator; Phase Phase 2, Phase 3; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-05-06 | NCT06487585 ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery) | Collaborator Lead: University of Maryland St. Joseph Medical Center | Phase 4 | Recruiting | Vasodilatory Hypotension During or After Cardiac Surgery | 100 | 2026-02 |
| 2023-12-04 | NCT06122987 Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock | Collaborator Lead: Kingman Regional Medical Center | Phase 4 | Unknown | Septic Shock; Shock; Sepsis; Systemic Inflammatory Response Syndrome | 50 | 2025-01 |
| 2023-04-17 | NCT05824767 Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock | Collaborator Lead: University of New Mexico | Phase 4 | Completed Results posted | Septic Shock; Vasodilatory Shock | 42 | 2025-03-12 |
| 2022-06-28 | NCT04901169 Angiotensin II in Liver Transplantation | Collaborator Lead: University of California, San Francisco | Phase 2, Phase 3 | Active not recruiting | Liver Transplant; Complications; Vasoplegia | 50 | 2027-03-18 |
| 2022-06-01 | NCT04904562 Angiotensin II for Distributive Shock | Collaborator Lead: Northwestern University | Phase 4 | Terminated Results posted | Distributive Shock | 2 | 2024-07-01 |
| 2022-01-03 | NCT05193370 Angiotensin II vs. Vasopressin in Septic Shock | Collaborator Lead: University of New Mexico | Phase 4 | Withdrawn | Septic Shock | 0 | 2022-11-30 |
| 2020-08-13 | NCT04529005 Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients | Collaborator Lead: University of Illinois at Chicago | Phase 4 | Completed Results posted | Shock, Surgical; Shock; Hypotension and Shock; Kidney Transplant; Complications; Intraoperative Hypotension; Postoperative Hypotension | 20 | 2021-08-01 |
| 2018-08 | NCT03623529 A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock | Lead sponsor | Phase 2 | Unknown | Catecholamine-resistant Hypotension (CRH); Distributive Shock; High Output Shock; Septic Shock | 100 | 2023-04 |
| 2018-02-11 | NCT03431077 A Study of LJPC-501 in Pediatric Patients With Hypotension | Lead sponsor | Phase 2 | Completed | Catecholamine-resistant Hypotension (CRH); Distributive Shock; High Output Shock; Sepsis | 2 | 2018-04-14 |
| 2017-11-30 | NCT03381833 A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia | Lead sponsor | Phase 2 | Terminated | Beta-Thalassemia | 84 | 2020-01-14 |
| 2017-11-29 | NCT03395704 A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis | Lead sponsor | Phase 2 | Completed Results posted | Hereditary Hemochromatosis | 70 | 2019-10-28 |
| 2015-03 | NCT02338843 A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension | Lead sponsor | Phase 3 | Completed Results posted | Catecholamine-resistant Hypotension (CRH); Distributive Shock; High Output Shock; Sepsis | 344 | 2017-02-18 |
| 2015-03 | NCT02312050 A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes | Lead sponsor | Phase 2 | Unknown | Diabetic Chronic Kidney Disease | 375 | 2016-12 |
| 2015-01 | NCT02333955 A Phase 2 Extension of Study GCS-100-CS-4003 | Lead sponsor | Phase 2 | Withdrawn | Chronic Kidney Disease | 0 | 2016-07 |
| 2014-03 | NCT01906307 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome | Lead sponsor | Phase 1 | Terminated | Hepatorenal Syndrome Type I and Type II | 6 | 2015-12 |
| 2014-01 | NCT02155673 A Phase 2 Extension Study of Study GCS-100-CS-4002 | Lead sponsor | Phase 2 | Completed | Chronic Kidney Disease | 92 | 2016-06 |
| 2013-06 | NCT01843790 A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease | Lead sponsor | Phase 2 | Completed | Chronic Kidney Disease | 120 | 2014-09 |
| 2013-01 | NCT01717248 Safety Study of GCS-100 to Treat Chronic Kidney Disease | Lead sponsor | Phase 1 | Completed | Chronic Kidney Disease | 29 | 2013-06 |
| 2008-07 | NCT00776802 GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Diffuse Large B-cell Lymphoma | 0 | 2009-04 |
| 2008-05 | NCT00609817 Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | Lead sponsor | Phase 1 | Terminated | Multiple Myeloma | 9 | 2009-04 |
| 2007-02 | NCT00514696 Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia | Lead sponsor | Phase 2 | Completed | Chronic Lymphocytic Leukemia | 12 | 2009-04 |
| 2006-09 | NCT00390091 Study of LJP 394 (Abetimus Sodium) in Lupus Patients | Lead sponsor | Phase 2 | Withdrawn | Systemic Lupus Erythematosus | 0 | |
| 2004-10 | NCT00089804 Study of LJP 394 in Lupus Patients With History of Renal Disease | Lead sponsor | Phase 3 | Terminated | Lupus Erythematosus, Systemic; Lupus Nephritis | 943 | 2009-02 |
| NCT03245528 Expanded Access for LJPC-501 | Lead sponsor | Expanded_access | Approved for marketing | Catecholamine Resistant Hypotension (CRH); Distributive Shock; High Output Shock; Sepsis; Vasodilatory Shock | |||
| NCT00035308 Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease | Lead sponsor | Phase 3 | Completed | Immunologic Diseases; Autoimmune Diseases; Systemic Lupus Erythematosus; Lupus Nephritis; Lupus Glomerulonephritis | 330 | 2002-12 |